Brian S Posner bought $40k of DYN
director at Dyne Therapeutics, Inc.. 2,500 shares at an average of $16.00, traded Oct 2, 2026, filed Oct 6, 2026.
Score components
- +15RoleDirector
- +6Trade size$40k at market
- +3Relative to holdingsHoldings up 10%
- +8Price context43% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-415584, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | POpen-market purchase Common Stock | +2,500 | $16.00 | $40k | 27,000 | 6 d ago |
Related signals
Other insiders at Dyne Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $107k 5,658 shares | -2% | |
| 20Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $116k 5,035 shares | -3% | |
| 15Weak | Dyne Therapeutics, Inc. | Johanna Friedl-Naderer Chief Commercial Officer | $25k 1,085 shares | -1% | |
| 11Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $41k 2,732 shares | -1% | |
| 27Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $55k 2,662 shares | -1% | |
| 10Weak | Dyne Therapeutics, Inc. | Johanna Friedl-Naderer Chief Commercial Officer | $2,984 144 shares | -0% | |
| 10Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $18k 880 shares | -1% | |
| 26Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $35k 2,640 shares | -1% | |
| 17Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $59k 4,425 shares | -5% | |
| 10Weak | Dyne Therapeutics, Inc. | Johanna Friedl-Naderer Chief Commercial Officer | $14k 1,038 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.